PLX5622
CAY-28927-1 1 mg
Data Sheet: 
SDS:
SDS:
CAS
1303420-67-8
Formulation
A crystalline solid
Purity
≥98%
MW
395,405466
Shipment
-20
Long Term Storage
-20
Shelf Life
1460
Description
A brain-penetrant CSF1R inhibitor (IC50 = 0.016 µM); selective for CSF1R over FLT3, Kit, Aurora C, and VEGFR2 (IC50s = 0.39, 0.86, 1, and 1.1 µM, respectively); greater than 100-fold selective for CSF1R over a panel of 230 kinases; reduces the number of Iba-1+ cells in the spinal cord dorsal horn in a mouse model of neuropathic pain induced by partial ligation of the sciatic nerve at 65 mg/kg; decreases macrophage levels of TNF-α and IL-1β and infiltration in the sciatic nerve and alleviates mechanical and cold allodynia in the same model; decreases the number of hippocampal microglia by 90%, as well as reduces the number and volume of retrosplenial and somatosensory cortical Aβ plaques in the 5XFAD mouse model of Alzheimer's disease at 1,200 ppm
ESCLUSIVAMENTE PER USO DI RICERCA (RUO) e non per uso terapeutico o diagnostico su uomini o animali. Il prodotto NON è un Dispositivo Medico o un Diagnostico in Vitro.
PRODUCT FOR RESEARCH USE ONLY (RUO) and not for therapeutic or diagnostic use on humans or animals. The product is NOT a Medical Device or an In-Vitro Diagnostic (IVD).
